D. Young

发表

Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective

M. Dragunow, M. During, P. Leone, 1999, Nature Medicine.

A novel role of circadian transcription factor DBP in hippocampal plasticity

M. Klugmann, M. During, D. Young, 2006, Molecular and Cellular Neuroscience.

Differential Actions of NPY on Seizure Modulation via Y1 and Y2 Receptors: Evidence from Receptor Knockout Mice

M. During, H. Herzog, K. Baer, 2006, Epilepsia.

Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs

E. Cornford, D. Young, J. Paxton, 2004, Cancer Chemotherapy and Pharmacology.

A novel bicistronic sensor vector for detecting caspase-3 activation.

D. Young, T. Vagner, A. Mouravlev, 2015, Journal of pharmacological and toxicological methods.

HSP70 and constitutively active HSF1 mediate protection against CDCrel-1-mediated toxicity.

M. During, H. Fitzsimons, D. Young, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy

M. Dragunow, M. Glass, M. During, 2014, Gene Therapy.

Platelet-Reactive Antibodies in Patients after Ischaemic Stroke—An Epiphenomenon or a Natural Protective Mechanism

M. During, M. Morel-Kopp, C. Ward, 2020, International journal of molecular sciences.

Induction of clusterin in the immature brain following a hypoxic-ischemic injury.

P. Gluckman, M. Dragunow, J. Dodd, 1996, Brain research. Molecular brain research.

Peroral gene therapy of lactose intolerance using an adeno-associated virus vector

R. Sherwin, M. Kaplitt, M. During, 1998, Nature Medicine.

MK-801 sensitizes rats to pilocarpine induced limbic seizures and status epilepticus.

M. Dragunow, D. Young, P. Hughes, 1993, Neuroreport.

Inhibition of NMDA receptor function with an anti-GluN1-S2 antibody impairs human platelet function and thrombosis

M. During, Peng Sun, Ting-Yu Chen, 2017, Platelets.

The NMDA Receptor Antibody Paradox: A Possible Approach to Developing Immunotherapies Targeting the NMDA Receptor

D. Young, 2020, Frontiers in Neurology.

Stroke Patients Develop Antibodies That React With Components of N-Methyl-D-Aspartate Receptor Subunit 1 in Proportion to Lesion Size

M. During, D. Wen, M. Kalev-Zylinska, 2013, Stroke.

Somatic gene transfer of cAMP response element-binding protein attenuates memory impairment in aging rats.

M. During, D. Young, A. Mouravlev, 2006, Proceedings of the National Academy of Sciences of the United States of America.

c-Jun promotes neurite outgrowth and survival in PC12 cells.

J. Lipski, M. Dragunow, M. During, 2000, Brain research. Molecular brain research.

Phosphorylation-dependent degradation of transgenic CREB protein initiated by heterodimerization

M. During, D. Young, A. Mouravlev, 2007, Brain Research.

CCAAT-enhancer binding proteinα is expressed in activated microglial cells after brain injury

P. Gluckman, M. Dragunow, E. Sirimanne, 1998 .

Neuronal Injury Following Electrically Induced Status Epilepticus with and without Adenosine Receptor Antagonism

M. Dragunow, D. Young, 1995, Experimental Neurology.

Using the immune system to target epilepsy.

M. During, D. Young, 2004, Advances in experimental medicine and biology.

Neuronal death and survival in two models of hypoxic-ischemic brain damage

M. Dragunow, E. Sirimanne, P. Lawlor, 1999, Brain Research Reviews.

Development and optimization of adeno-associated virus vector transfer into the central nervous system.

M. Klugmann, M. During, K. Baer, 2003, Methods in molecular medicine.

Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms

M. Dragunow, D. Young, 1994, Neuroscience.

An Immunological Approach to Increase the Brain's Resilience to Insults

M. Klugmann, M. During, Claudia B. Klugmann, 2014, ISRN neuroscience.

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

M. Klugmann, M. During, H. Fitzsimons, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes

M. Dragunow, M. During, Q. Chen, 2001, Gene Therapy.

Transcriptional activity of novel ALDH1L1 promoters in the rat brain following AAV vector-mediated gene transfer

D. Young, Janitha Mudannayake, A. Mouravlev, 2016, Molecular therapy. Methods & clinical development.

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

David Eidelberg, Chengke Tang, D. Eidelberg, 2007, The Lancet.

Gene Therapy for Huntington’s Disease

D. Young, Dahna Fong, Angela Wu, 2015 .

Nucleic Acid-Based Therapy Approaches for Huntington's Disease

D. Young, T. Vagner, A. Mouravlev, 2012, Neurology research international.

Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels

T. Golde, M. During, P. Das, 2007, Molecular Neurodegeneration.

Bax expression in mammalian neurons undergoing apoptosis, and in Alzheimer's disease hippocampus

P. Gluckman, M. Dragunow, E. Sirimanne, 1997, Brain Research.

An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy.

J. Lipski, M. During, D. Poulsen, 2000, Science.

Is c-Jun involved in nerve cell death following status epilepticus and hypoxic-ischaemic brain injury?

P. Gluckman, M. Dragunow, E. Sirimanne, 1993, Brain Research. Molecular Brain Research.

Trk receptor alterations in Alzheimer's disease.

R. Faull, M. Dragunow, R. Faull, 1996, Brain research. Molecular brain research.

VEGF links hippocampal activity with neurogenesis, learning and memory

M. During, Lei Cao, Yuhong Liu, 2004, Nature Genetics.

Long-Term Follow-Up After Gene Therapy for Canavan Disease

D. Shera, Andrew Freese, M. During, 2012, Science Translational Medicine.

Brain-derived neurotrophic factor is reduced in Alzheimer's disease.

R. Faull, M. Dragunow, B. Synek, 1997, Brain research. Molecular brain research.

AAV Targeting of Glial Cell Types in the Central and Peripheral Nervous System and Relevance to Human Gene Therapy

S. O'Carroll, D. Young, William H Cook, 2021, Frontiers in Molecular Neuroscience.

MK‐801 and NBQX prevent electrically induced status epilepticus

M. Dragunow, D. Young, 1994, Neuroreport.

Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington's Disease.

D. Young, 2016, Methods in molecular biology.

Do c‐Jun, c‐Fos, and amyloid precursor protein play a role in neuronal death or survival?

P. Gluckman, M. Dragunow, E. Sirimanne, 1998, Journal of neuroscience research.

Aβ Infusion and Related Models of Alzheimer Dementia

P. Lawlor, D. Young, Patricia A. Lawlor, 2011 .

AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats

M. Klugmann, M. During, D. Young, 2005, Molecular and Cellular Neuroscience.

Knockdown and overexpression of NR1 modulates NMDA receptor function

M. During, M. Kalev-Zylinska, D. Young, 2009, Molecular and Cellular Neuroscience.

Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury

S. O'Carroll, D. Young, J. Griffin, 2019, Gene Therapy.

Recombinant AAV‐mediated expression of galanin in rat hippocampus suppresses seizure development

M. During, A. Vezzani, K. Baer, 2003, The European journal of neuroscience.

Astrocyte-selective AAV-ADAMTS4 gene therapy combined with hindlimb rehabilitation promotes functional recovery after spinal cord injury

S. O'Carroll, D. Young, J. Griffin, 2019, Experimental Neurology.

AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease.

M. Dragunow, M. During, A. Kells, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.

T. Serikawa, M. Klugmann, M. During, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Long-Term Follow-Up After Gene Therapy for

D. Shera, Andrew Freese, M. During, 2016 .

Identification and distribution of aspartoacylase in the postnatal rat brain

T. Serikawa, M. Klugmann, M. During, 2003, Neuroreport.

Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.

M. During, Matthew J During, Patricia A Lawlor, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Heat shock factor HSF1 regulates BDNF gene promoters upon acute stress in the hippocampus, together with pCREB

K. Sakata, F. Liao, D. Young, 2022, Journal of neurochemistry.

Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury

S. O'Carroll, D. Young, J. Griffin, 2019, Gene Therapy.

Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics

D. Kullmann, S. Schorge, A. Snowball, 2019, Science Advances.

Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABAB receptors in scopolamine‐induced amnesia

M. During, R. Quirion, D. Young, 2007, Journal of neurochemistry.

Gene Regulation Systems for Gene Therapy Applications in the Central Nervous System

D. Young, Jerusha Naidoo, 2012, Neurology research international.

Clusterin accumulates in dying neurons following status epilepticus.

M. Dragunow, J. Dodd, P. Lawlor, 1995, Brain research. Molecular brain research.

Differential expression of inducible transcription factors in basal ganglia neurons.

M. Dragunow, P. Lawlor, D. Young, 1995, Brain research. Molecular brain research.

Differential regulation by MK801 of immediate-early genes, brain-derived neurotrophic factor and trk receptor mRNA induced by a kindling after-discharge.

M. Dragunow, Q. Yan, D. Young, 1998, Brain research. Molecular brain research.

AAV-Mediated Overexpression of Neuroserpin in the Hippocampus Decreases PSD-95 Expression but Does Not Affect Hippocampal-Dependent Learning and Memory

M. During, N. Birch, D. Young, 2014, PloS one.

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

M. Klugmann, M. During, H. Fitzsimons, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

CCAAT-enhancer binding protein alpha is expressed in activated microglial cells after brain injury.

P. Gluckman, M. Dragunow, E. Sirimanne, 1998, Brain research. Molecular brain research.

Pharmacokinetics and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse

E. Cornford, D. Young, P. Kestell, 2004, Cancer Chemotherapy and Pharmacology.

Non‐NMDA glutamate receptors are involved in the maintenance of status epilepticus

M. Dragunow, D. Young, 1993, Neuroreport.